View Author
Segeren, C.M.
( C.M. Segeren)
patient myeloma treatment therapy study survival group transplantation chemotherapy response blood month autologou melphalan high-dose marrow cell transplantation analysis cycle cell rescue glucocorticoid randomized disease response rate chromosome myelo-ablative remission high-dose therapy receptor factor abnormality plasma progression br j haematol regimen induction chapter trial effect prognostic level j clin oncol result rescue hospital tumor chemotherapy group table allogeneic transplant expression bone marrow transplant allo-sct stage number plasma cells myelo-ablative therapy event-free survival dexamethasone myelo-ablative treatment toxicity cytogenetic serum center myeloablative figure phase relapse follow-up infusion quality prognostic factors myeloma cells cancer cell support deletion maintenance myeloma patients chromosome 13 interferon
3 Most Recent Publications
|
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
(Article)
Segeren, C.M. Wijermans, P.W. Biesma, D.H. Croockewit, A.J. Verhoef, G.E.G. Cornelissen, J.J. Marwijk Kooy, M. van Slater, R. Schaafsma, M.R. Buijt, I. Oers, M.H.J. van Wittebol, S. Baars, J.W. Fibbe, W.E. Sonneveld, P. Holt, B. van der Steijaert, M.M. Vellenga, E. Lokhorst, H.M. |
2003-01-01
|
|
Intensive therapy in multiple myeloma
(Doctoral Thesis)
Segeren, C.M. |
2002-09-13
|
|
Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells
(Article)
Lange, P. de Segeren, C.M. Koper, J.W. Sonneveld, P. Brinkmann, A.O. White, A. Brogan, I.J. Jong, F.H. de Lamberts, S.W.J. Wiemer, E.A.C. |
2001-01-01
|
